Related Experiment Video
Updated: Aug 13, 2026
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
Cardiac Contractility Modulation: Implications in Heart Failure, a Current Review
Alexander L Wallner1, Salvatore Savona1, Rami Kahwash1
1Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Cardiac Electrophysiology Clinics
|August 11, 2026
Summary
Cardiac contractility modulation (CCM) is a new heart failure therapy using nonexcitatory electrical stimulation. It improves contractility, symptoms, and quality of life for eligible patients.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Heart failure (HF) significantly impacts patient quality of life.
- Optimal medical therapy (OMT) and cardiac resynchronization therapy (CRT) are standard treatments.
- A subset of HF patients remain symptomatic despite OMT and are not candidates for CRT.
Purpose of the Study:
- To introduce Cardiac Contractility Modulation (CCM) as a novel therapeutic option.
- To describe the mechanism and patient selection for CCM therapy.
Main Methods:
- CCM utilizes nonexcitatory electrical stimulation during the cardiac cycle's absolute refractory period.
- Stimulation is delivered to the myocardium to enhance contractility.
Main Results:
- CCM increases cardiac contractility.
- This leads to improvements in heart failure symptoms.
- Functional status and quality of life are also enhanced.
Conclusions:
- CCM provides an expanded treatment option for symptomatic heart failure patients.
- It is indicated for patients with LVEF 25-45% on OMT and not eligible for CRT.
- CCM offers a new approach to managing heart failure in specific patient populations.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...